| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5699338 | Clinical Oncology | 2010 | 8 Pages |
Abstract
The recent availability of molecular targeted therapies leads to reconsideration of the treatment strategy in patients with distant metastases from differentiated thyroid carcinoma who are resistant to radioiodine therapy, and in patients with metastatic medullary thyroid carcinoma. In patients with progressive disease, treatment with kinase inhibitors should be offered, preferably in the context of a prospective trial.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
C. Chougnet, M. Brassard, S. Leboulleux, E. Baudin, M. Schlumberger,